Literature DB >> 32152720

Transarterial Ethanol Ablation for Small Hepatocellular Carcinoma (≤ 3 cm): A Comparative Study Versus Radiofrequency Ablation.

Simon Chun Ho Yu1,2, Joyce Wai Yi Hui3,4, Charing Ching Ning Chong5, Cheuk Man Chu3,4, Sunny Cheung5, John Wong5, Kit Fai Lee5.   

Abstract

PURPOSE: The objective was to evaluate the local treatment efficacy of transarterial ethanol ablation (TEA) as compared to radiofrequency ablation (RFA) for small hepatocellular carcinoma (HCC).
MATERIALS AND METHODS: This was a retrospective study between January 2005 and April 2017, in which the treatment outcomes of all patients who received either percutaneous TEA or RFA for HCC tumors of size ≤ 3 cm, of Child-Pugh grade A or B, received no prior treatment other than surgical resection, were compared. For TEA, a mixture of absolute ethanol and ethiodized oil at a proportion of 1:2 by volume was administered superselectively into the tumor via a microcatheter placed at the feeding arteries. The TEA group and the RFA group consisted of 68 consecutive patients (88 treated target tumors) and 129 consecutive patients (129 tumors), respectively.
RESULTS: Technical success was achieved in all the target tumors in both groups. Grade 3 complication (CIRSE Classification) of prolonged fever occurred in 3 cases with multi-focal and large tumors in the TEA group. There was no statistically significant difference in complete response rate between the TEA group (84/88 or 95.5%) and the RFA group (188/195 or 96.4%) (p = 0.7). Time to progression in the TEA group [median 11.9 months, interquartile range (IQR) 5.6-18 months] was not statistically different from that in the RFA group (median 9.5 months, IQR 3.5-18.7 months) (p = 0.773).
CONCLUSION: TEA could be an effective alternative of RFA for the local treatment of small HCC; it is especially valuable for tumors of unfavorable location.

Entities:  

Keywords:  Comparative study; Hepatocellular carcinoma; Local regional therapy; Radiofrequency ablation; Transarterial ethanol ablation; Treatment response

Year:  2020        PMID: 32152720     DOI: 10.1007/s00270-020-02426-4

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.740


  2 in total

1.  Comparison of Survival Outcomes in Transarterial Ethanol Ablation and Liver Resection for Solitary Hepatocellular Carcinoma ≤ 5 cm in Patients Stratified by Liver Function.

Authors:  Simon Chun Ho Yu; Joyce Wai Yi Hui; Charing Ching Ning Chong; Carmen Chi Min Cho; Sunny Cheung; John Wong; Kit Fai Lee
Journal:  Cardiovasc Intervent Radiol       Date:  2021-10-05       Impact factor: 2.740

2.  Ultrasound-Guided Percutaneous Ethanol-Paclitaxel Combined Therapy for Rabbit VX2 Liver Tumors.

Authors:  Li Chen; Zhi-Xing Liu; Qiu-Chen Bi; Jun Zhao; Qing-Rong Liang; Qun Tang
Journal:  J Hepatocell Carcinoma       Date:  2021-04-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.